Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005
- PMID: 16319813
Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005
Abstract
Clostridium difficile is a spore-forming, gram-positive bacillus that produces exotoxins that are pathogenic to humans. C. difficile-associated disease (CDAD) ranges in severity from mild diarrhea to fulminant colitis and death. Antimicrobial use is the primary risk factor for development of CDAD because it disrupts normal bowel flora and promotes C. difficile overgrowth. C. difficile typically has affected older or severely ill patients who are hospital inpatients or residents of long-term-care facilities. Recently, however, both the frequency and severity of health-care-associated CDAD has increased; from 2000 to 2001, the rate of U.S. hospital discharge diagnoses of CDAD increased by 26%. One possible explanation for these increases is the emergence of a previously uncommon strain of C. difficile responsible for severe hospital outbreaks. Although individual cases of CDAD are not nationally reportable, in 2005, the Pennsylvania Department of Health (PADOH) and CDC received several case reports of serious CDAD in otherwise healthy patients with minimal or no exposure to a health-care setting. An investigation was initiated by the Philadelphia Department of Public Health (PDPH), PADOH, and CDC to determine the scope of the problem and explore a possible change in CDAD epidemiology. This report summarizes the results of the investigation in Pennsylvania and three other states, which indicated the presence of severe CDAD in healthy persons living in the community and peripartum women, two populations previously thought to be at low risk. The findings underscore the importance of judicious antimicrobial use, the need for community clinicians to maintain a higher index of suspicion for CDAD, and the need for surveillance to better understand the changing epidemiology of CDAD.
Similar articles
-
Surveillance for community-associated Clostridium difficile--Connecticut, 2006.MMWR Morb Mortal Wkly Rep. 2008 Apr 4;57(13):340-3. MMWR Morb Mortal Wkly Rep. 2008. PMID: 18385641
-
Clostridium difficile is no longer just a nosocomial infection or an infection of adults.Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S42-5. doi: 10.1016/S0924-8579(09)70016-0. Int J Antimicrob Agents. 2009. PMID: 19303569 Review.
-
Community-onset Clostridium difficile-associated diarrhoea not associated with antibiotic usage--two case reports with review of the changing epidemiology of Clostridium difficile-associated diarrhoea.Neth J Med. 2008 May;66(5):207-11. Neth J Med. 2008. PMID: 18490799 Review.
-
The challenges posed by reemerging Clostridium difficile infection.Clin Infect Dis. 2007 Jul 15;45(2):222-7. doi: 10.1086/518874. Epub 2007 Jun 4. Clin Infect Dis. 2007. PMID: 17578783 Review.
-
Emergence of Clostridium difficile-associated disease in North America and Europe.Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18. doi: 10.1111/j.1469-0691.2006.01580.x. Clin Microbiol Infect. 2006. PMID: 16965399 Review.
Cited by
-
Antibiotic resistance of enteropathogenic bacteria in a teaching hospital in North Khuzestan during a three-year period.J Family Med Prim Care. 2024 May;13(5):2073-2077. doi: 10.4103/jfmpc.jfmpc_1594_23. Epub 2024 May 24. J Family Med Prim Care. 2024. PMID: 38948633 Free PMC article.
-
Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study.Saudi Pharm J. 2023 Sep;31(9):101736. doi: 10.1016/j.jsps.2023.101736. Epub 2023 Aug 5. Saudi Pharm J. 2023. PMID: 37638216 Free PMC article.
-
Clostridioides difficile infection in liver cirrhosis patients: A population-based study in United States.World J Hepatol. 2021 Aug 27;13(8):926-938. doi: 10.4254/wjh.v13.i8.926. World J Hepatol. 2021. PMID: 34552699 Free PMC article.
-
Rapid Classification of Clostridioides difficile Strains Using MALDI-TOF MS Peak-Based Assay in Comparison with PCR-Ribotyping.Microorganisms. 2021 Mar 23;9(3):661. doi: 10.3390/microorganisms9030661. Microorganisms. 2021. PMID: 33806749 Free PMC article.
-
Fidaxomicin Use for Clostridium Difficile Infection Probably Decreases the Effect of Coumadin® in Elderly.Cureus. 2020 Dec 5;12(12):e11915. doi: 10.7759/cureus.11915. Cureus. 2020. PMID: 33425501 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
